Zinaida Good, PhD

Zinaida Good is an instructor and a PICI Bridge Fellow working at the interface between systems biology and cancer immunotherapy at Stanford University. Dr. Good’s research with Crystal L. Mackall, MD, and Sylvia K. Plevritis, PhD, focuses on investigating why CAR T-cell therapies succeed or fail in patients; they recently identified CAR T regulatory cells as a correlate of progression and reduced toxicity following CD19-CAR therapy for large B-cell lymphoma.

Dr. Good’s work includes four first-author papers, 12 co-authored papers and two patent applications. Her academic potential has been recognized by prestigious postdoctoral fellowships — PICI Scholar 2018 and Stanford Cancer Institute 2020 — and she was named an Arthur and Sandra Irving Cancer Immunology Fellow in 2022. As a 2023 PICI Bridge Fellow, Dr. Good is preparing to launch an independent research program with a long-term goal of understanding and enhancing engineered cellular immunotherapies for patients with cancer.

Dr. Good holds a PhD in computational and systems immunology from Stanford University, where she trained with Garry P. Nolan, PhD, and Sean C. Bendall, PhD. Her background is in immunology (BS and MS from the University of British Columbia in Vancouver) and oncology (she worked for two years in discovery oncology at Genentech).

View Dr. Good’s YouTube Short.

• Present: Stanford University, Stanford, CA, Instructor
• 2018-2023: Stanford University, Postdoc, Systems Biology / Immunology
• 2018: Stanford University, Stanford, CA, PhD, Computational & Systems Immunology
• 2012: UBC, Vancouver, BC, Canada, MS, Microbiology & Immunology
• 2008: UBC, Vancouver, BC, Canada, BS, Microbiology & Immunology